23andMe cuts 40% of its workforce and ends cancer research to stabilize finances.

Genetic testing company 23andMe is cutting 40% of its workforce and discontinuing its therapeutics division, including cancer research programs, in an effort to stabilize the company's financial situation. Over 200 jobs will be lost as part of this restructuring.

November 11, 2024
107 Articles

Further Reading